image
2 known investors
Exagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.
Investors · 2
In the news
- XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Ratinggurufocus.com · 2026
- Exagen Inc. Reports First Quarter 2026 Results - BioSpacebiospace.com · 2026
- Exagen earnings beat by $0.05, revenue topped estimates By Investing.cominvesting.com · 2026
- Record Revenue Growth and Higher Test Pricing Keep Exagen (XGN) in Focus Despite Ongoing Lossesfinance.yahoo.com · 2026
- Exagen - 2026 Company Profile, Funding, Competitors & Financials - Tracxntracxn.com · 2021
- Exagen Inc. Completes $22.6 Million Financing – Exagen Inc.exagen.com · 2019